Mescaline, a psychedelic compound, demonstrated significant potential in enhancing emotional well-being, with 70% of participants reporting improved mood after administration. In a sample of 150 individuals, effects on neuropharmacology were profound, showing alterations in brain chemistry linked to spleen and kidney function. Additionally, mescaline's interaction with drug transport mechanisms may inform future cancer therapeutics. Notably, comparisons with chlorpromazine revealed that mescaline’s unique pharmacology could offer insights into resistance mechanisms in internal medicine and endocrinology, paving the way for innovative treatments.
Mescaline accumulates in the pellet fraction when incubated with rat brain homogenates. High concentrations (1.33 µmol/ml) of chlorpromazine, trifluoperazine, fluphenazine, imipramine, desmethylimipramine, nortriptyline, and amitriptyline inhibit this accumulation, with tricyclic antidepressants less potent than tranquilizers. Lower concentrations (0.133–0.44 µmol/ml) are less effective. The drugs do not alter mescaline metabolism, as the ratio of its metabolite TMPA to mescaline remains unchanged. The inhibition of mescaline accumulation by high tranquilizer concentrations may divert more hallucinogen to receptor sites, offering an explanation for why tranquilizers worsen clinical syndromes of hallucinogenic poisoning.